A small biotech may be ideal for developing a new
Post# of 30028
Posted On: 07/15/2014 7:26:09 AM
A small biotech may be ideal for developing a new drug for Wolfram?
I feel that a small biotech may be ideal for developing a new drug for a rare disease like Wolfram syndrome. A small biotech has a narrow focus, which may be suitable for creating a drug targeting a specific pathway and a specific disease. Mr. John Crowley and Dr. William Canfied (trained in Internal Medicine at Washington University) took this strategy and created a novel drug for Pompe Disease. They started a company in 2000, and Mr. Crowley's children with Pompe disease received their drug in 2003. Their small biotech was eventually acquired by Genzyme.
I feel that a small biotech may be ideal for developing a new drug for a rare disease like Wolfram syndrome. A small biotech has a narrow focus, which may be suitable for creating a drug targeting a specific pathway and a specific disease. Mr. John Crowley and Dr. William Canfied (trained in Internal Medicine at Washington University) took this strategy and created a novel drug for Pompe Disease. They started a company in 2000, and Mr. Crowley's children with Pompe disease received their drug in 2003. Their small biotech was eventually acquired by Genzyme.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼